The European Commission (EC) has granted Marketing Authorization for Bristol Myers Squibb’s (NYSE: BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a differentiated CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy.
The Marketing Authorization, which authorizes the use of Breyanzi in all European Union (EU) member states, is based on results from the TRANSCEND NHL 001 and TRANSCEND WORLD studies evaluating the drug in adult patients with R/R DLBCL, PMBCL and FL3B, including those with a broad range of histologies and high-risk disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze